Losartan for Adolescents (Ages 12 to 17): Complete Caregiver Administration Guide

At a glance
- FDA approval / approved for hypertension in pediatric patients ≥6 years old
- Standard starting dose / 0.7 mg/kg/day orally, once daily
- Maximum dose / 1.4 mg/kg/day or 100 mg/day (whichever is lower)
- Available forms / 25 mg, 50 mg, 100 mg tablets; compounded 2.5 mg/mL oral suspension
- Drug class / Angiotensin II receptor blocker (ARB)
- Key monitoring / Blood pressure, serum potassium, serum creatinine
- Pregnancy risk / Category D, must not be used if teen could be pregnant
- Missed-dose rule / Take as soon as remembered; skip if next dose is within 6 hours
- Caregiver alert / Avoid NSAIDs, potassium supplements, and salt substitutes without prescriber approval
Why Adolescents Are Prescribed Losartan
Hypertension affects roughly 4% of U.S. Children and adolescents, with rates rising alongside childhood obesity. Losartan belongs to the ARB drug class, meaning it blocks angiotensin II at the AT1 receptor to relax blood vessels and lower blood pressure. The FDA approved losartan (Cozaar) for pediatric hypertension in patients 6 years and older based on pharmacokinetic and efficacy data reviewed in the agency's labeling documents. [1][2]
What Conditions Lead to This Prescription
Adolescents most commonly receive losartan for:
- Primary (essential) hypertension, increasingly common in teens with obesity or family history
- Chronic kidney disease (CKD), losartan slows proteinuria progression, which makes it a preferred agent when kidney disease drives blood pressure elevation [3]
- Diabetic nephropathy, though rare at this age, some adolescents with type 1 diabetes develop early proteinuria that losartan may reduce [4]
- Marfan syndrome, off-label use targets aortic root dilation, supported by trial data in pediatric populations [5]
How the Drug Works
Losartan selectively blocks the angiotensin II type 1 (AT1) receptor. Blocking AT1 prevents vasoconstriction and aldosterone secretion, reducing both vascular resistance and sodium retention. The active metabolite, EXP3174, is approximately 10 to 40 times more potent than the parent compound and accounts for most of the antihypertensive effect. [1]
The American Academy of Pediatrics (AAP) 2017 clinical practice guideline on pediatric hypertension recommends ARBs as first-line agents when hypertension accompanies CKD with proteinuria in adolescents, specifically citing angiotensin-blocking agents as the class of choice in that setting. [6]
FDA-Approved Dosing for Ages 12 to 17
The FDA-approved starting dose for adolescents is 0.7 mg/kg/day once daily, not to exceed 50 mg/day at initiation. The prescriber may titrate upward to a maximum of 1.4 mg/kg/day or 100 mg/day, whichever is lower. [1]
Weight-Based Dosing Table
| Teen's Weight | Starting Dose (0.7 mg/kg) | Approximate Tablet | |---|---|---| | 30 kg (66 lb) | 21 mg | 25 mg tablet | | 40 kg (88 lb) | 28 mg | 25 mg or 50 mg tablet | | 50 kg (110 lb) | 35 mg | 50 mg tablet | | 60 kg (132 lb) | 42 mg | 50 mg tablet | | 70 kg (154 lb) | 49 mg | 50 mg tablet |
Doses are typically rounded to the nearest commercially available tablet strength. When precise weight-based dosing is required, the prescriber may order a compounded 2.5 mg/mL oral suspension. [1][2]
Tablet vs. Oral Suspension
Tablets are the preferred form for most adolescents. Losartan is available as 25 mg, 50 mg, and 100 mg scored tablets. Tablets can be split but should not be crushed and mixed into food unless the prescriber has specifically approved a compounded preparation.
Oral suspension at 2.5 mg/mL can be compounded by a specialty pharmacy using losartan tablets and Ora-Plus/Ora-Sweet SF vehicle. The FDA label provides a validated compounding recipe yielding a stable suspension for up to 4 weeks when refrigerated. [1] Shake the bottle for 10 seconds before every dose and use the oral syringe provided, never a household teaspoon.
Step-by-Step Caregiver Administration Instructions
Giving losartan correctly on a consistent schedule produces the most stable blood pressure control. These steps apply to both tablet and suspension forms.
Before the First Dose
- Confirm the weight-based dose in writing with the prescribing clinician.
- Pick a fixed daily time. Once-daily dosing works best when linked to a routine (morning meal, evening tooth-brushing). Consistency within a 2-hour window each day is sufficient.
- Check for drug interactions before starting: NSAIDs such as ibuprofen reduce losartan's antihypertensive effect and increase nephrotoxicity risk. [7] Potassium-sparing diuretics (spironolactone, triamterene) and potassium supplements raise the risk of hyperkalemia when combined with any ARB. [1]
- If the teen takes lithium, alert the prescriber. ARBs raise lithium serum levels by reducing renal clearance, which may push lithium into the toxic range. [1]
Giving the Tablet
- Give with or without food, food does not significantly alter losartan bioavailability. [1]
- Have the teen swallow the tablet with a full glass of water (240 mL).
- Do not crush tablets to mix into juice or yogurt unless using a pharmacy-verified compounded suspension.
Giving the Oral Suspension
- Remove from refrigerator 5 minutes before dosing.
- Shake vigorously for 10 seconds.
- Draw the prescribed volume into the calibrated oral syringe.
- Place the syringe tip just inside the cheek, not at the back of the throat, and deliver slowly.
- Follow immediately with 60 to 120 mL of water to rinse the mouth and ensure full delivery.
- Record the dose time in a caregiver log or phone app. [2]
Handling a Missed Dose
Give the missed dose as soon as you remember. If the next scheduled dose is within 6 hours, skip the missed dose entirely and resume the regular schedule. Never double-dose. Doubling a dose can produce a sharp drop in blood pressure (hypotension), causing dizziness or fainting in an active teenager. [1]
Blood Pressure Monitoring at Home
Accurate home monitoring guides the prescriber's dose adjustments and catches uncontrolled hypertension before it causes end-organ stress.
Equipment and Technique
Use an oscillometric upper-arm device with a cuff sized to the teen's arm circumference (not age). The AAP recommends that the cuff bladder length cover 80 to 100% of arm circumference and the width cover 40%. [6] Wrist or finger monitors are less accurate for this age group and should not be substituted.
Measure at the same time each day, ideally in the morning before the dose. Record three readings 2 minutes apart and average the last two. [6]
Target Blood Pressure Values
The AAP 2017 guideline defines normotension in adolescents 13 years and older as below 120/80 mmHg and considers readings of 130/80 mmHg or above as stage 1 hypertension in this group. [6] The prescriber will set an individualized target, especially for teens with CKD, where the goal may be below the 50th percentile for age, sex, and height.
A simple three-zone caregiver monitoring framework:
| Reading Zone | Action | |---|---| | Below target set by prescriber | Continue current dose; document | | 10 to 20 mmHg above target | Recheck in 30 minutes; contact prescriber same day if persistent | | >20 mmHg above target OR any systolic >160 | Contact prescriber immediately or seek urgent care |
Laboratory Monitoring Requirements
Losartan affects kidney function and serum electrolytes. These labs are not optional in adolescents on long-term therapy.
What Gets Checked and When
At baseline before starting, the prescriber should obtain: serum creatinine, estimated GFR, serum potassium, urinalysis with protein-to-creatinine ratio (if CKD is present), and a pregnancy test for female teens. [1][6]
After starting or changing the dose, labs are typically rechecked at 4 weeks and then every 3 to 6 months once stable. A study published in Pediatric Nephrology found that ARB-related hyperkalemia occurs in approximately 5% of pediatric CKD patients, making potassium monitoring especially relevant for teens with reduced kidney function. [3]
Potassium: The Electrolyte to Watch Most Closely
ARBs reduce aldosterone, which causes the kidney to retain potassium. Serum potassium above 5.5 mEq/L in an adolescent warrants a call to the prescriber before giving the next dose. [1][8] Caregivers should also avoid giving potassium-containing salt substitutes (KCl-based products sold as "low-sodium" salt) without explicit prescriber approval.
Recognizing and Managing Side Effects
Most adolescents tolerate losartan well. The clinical trial data supporting pediatric approval showed a safety profile comparable to placebo for most adverse events. [2] Still, caregivers must know which symptoms require prompt action.
Common and Usually Mild Side Effects
- Dizziness or lightheadedness, most often occurs in the first 1 to 2 weeks as blood pressure adjusts. Encourage the teen to stand up slowly from seated or lying positions (orthostatic precaution). Usually resolves without dose change.
- Fatigue, reported in a small subset; typically transient.
- Upper respiratory infections, more common with ARBs than with ACE inhibitors because ARBs do not cause the bradykinin-mediated cough. Losartan itself does not cause cough in most patients. [9]
- Hyperkalemia (elevated potassium), watch for muscle weakness, irregular heartbeat, or extreme fatigue; check labs if these appear. [8]
Side Effects That Require Immediate Medical Attention
Angioedema is rare with ARBs but can occur, particularly in teens who have previously experienced angioedema with an ACE inhibitor. Swelling of the face, lips, tongue, or throat requires emergency care. [1] ARB-associated angioedema is estimated to occur in approximately 0.1 to 0.7% of ARB users, a rate lower than the 1 to 3% seen with ACE inhibitors. [9]
Acute kidney injury may present as dramatically reduced urine output, swelling in the legs, or sudden fatigue. This is most likely in teens who are dehydrated from illness, vomiting, or intense exercise in heat. Losartan should be held and the prescriber contacted if the teen cannot maintain adequate fluid intake for more than 24 hours. [1][7]
Hypotension (blood pressure that drops too low) may cause syncope during sports. If the teen faints or feels profoundly dizzy, lay them flat, raise the legs, and call 911 if consciousness is not regained in under 60 seconds.
Pregnancy Risk: Category D
Losartan carries FDA Pregnancy Category D status. Exposure during the second and third trimesters causes fetal renal dysplasia, oligohydramnios, and neonatal renal failure. [1][10] For any adolescent female who could become sexually active, the prescriber must document contraception counseling before and during losartan therapy. Caregivers should know that this discussion is a required part of safe prescribing and not an optional conversation.
Drug and Food Interactions Caregivers Must Know
Medications to Avoid or Monitor
- NSAIDs (ibuprofen, naproxen, diclofenac): Reduce antihypertensive effect and increase acute kidney injury risk. A systematic review confirmed that combined NSAID and ARB use elevates the odds of AKI by approximately 2-fold. [7] Use acetaminophen for pain and fever management instead.
- Potassium-sparing diuretics (spironolactone, eplerenone, triamterene): Combined with losartan, these significantly raise hyperkalemia risk. [1][8]
- Lithium: ARBs reduce lithium renal clearance and may push serum levels above the 1.2 mEq/L therapeutic ceiling, potentially causing lithium toxicity. Monitor lithium levels within 2 weeks of starting or stopping losartan. [1]
- Other antihypertensives: Additive blood pressure lowering is expected. Dose adjustments may be needed if the teen also takes a beta-blocker, calcium channel blocker, or diuretic. [1]
- Rifampicin: This antibiotic (sometimes used in tuberculosis treatment) induces CYP2C9 and reduces losartan's conversion to its active metabolite, EXP3174, potentially blunting effectiveness. [1]
Foods and Supplements
Salt substitutes containing potassium chloride can raise serum potassium to dangerous levels when used alongside an ARB. [8] High-potassium foods (bananas, avocado, spinach) in typical dietary amounts are generally safe, but binge consumption of potassium supplements is not. Grapefruit and grapefruit juice do not significantly interact with losartan (unlike with many calcium channel blockers), so no restriction is needed on that front. [1]
Special Situations Caregivers Frequently Encounter
Illness, Vomiting, and Dehydration
When an adolescent has gastroenteritis with repeated vomiting or diarrhea, the kidneys become dependent on adequate fluid volume to maintain perfusion. Using an ARB during significant dehydration raises AKI risk substantially. [7] The standard clinical guidance ("sick-day rules") recommends temporarily holding losartan if the teen cannot keep fluids down for more than 24 hours, has two or more episodes of vomiting in 24 hours, or has signs of moderate dehydration such as reduced urination and dry mouth. Call the prescriber before holding the medication so dosing can be formally paused rather than just missed. [6]
Sports, Exercise, and Heat Exposure
Vigorous exercise and heat cause peripheral vasodilation and sodium loss through sweat. Both effects are additive with losartan's antihypertensive mechanism, creating a window where blood pressure may fall below the teen's usual baseline. [6] Caregivers should confirm with the prescriber whether blood pressure should be checked before and after intense practice sessions during the first month of therapy. Adequate hydration before, during, and after exercise is especially relevant.
Dental Procedures and Minor Surgery
Inform every dentist or surgeon that the teen takes losartan. Local anesthetics with epinephrine can cause transient blood pressure spikes that may interact with antihypertensive therapy. Most dental procedures can proceed normally, but the prescriber should be notified so a coordinated plan is in place. [1]
Switching Between Brand and Generic
Losartan is available as the brand Cozaar and numerous generic formulations. FDA bioequivalence standards require that generics fall within 80 to 125% of the brand's pharmacokinetic parameters, which is acceptable for most patients. Still, if the teen's blood pressure changes unexpectedly after a pharmacy switch to a different manufacturer, report this to the prescriber. [2]
Caregiver Communication With the Prescribing Team
The 2017 AAP hypertension guideline recommends that pediatric patients on antihypertensive therapy have blood pressure reassessed within 4 weeks of a dose change and at least every 6 months once stable. [6] Many adolescents are seen less frequently in practice, which places more responsibility on caregivers to track readings and report concerns proactively.
What to Log Between Visits
- Date, time, and blood pressure reading (both numbers)
- Time the day's losartan dose was given
- Any missed doses and the reason
- New medications, supplements, or herbal products started
- Symptoms: headache, dizziness, fatigue, palpitations, reduced urination
Bring this log (paper or phone screenshot) to every appointment. Prescribers who see documented trends can make better titration decisions than those working from a single office reading.
When to Call Before the Next Appointment
Contact the prescriber same-day or urgently for:
- Systolic blood pressure persistently >150 mmHg on two consecutive readings 30 minutes apart
- Serum potassium above 5.5 mEq/L on a home fingerstick test or lab result
- Any facial or throat swelling (potential angioedema)
- Confirmed or suspected pregnancy
- Starting a new medication, especially an NSAID, potassium supplement, or diuretic
- Inability to take the medication for more than 48 hours due to illness
Frequently asked questions
›What is the correct dose of losartan for a 14-year-old?
›Can a teenager take losartan with food?
›What happens if my teen misses a dose of losartan?
›Does losartan cause a cough in teenagers?
›Can my teen take ibuprofen for pain while on losartan?
›Is losartan safe for female teenagers who might become pregnant?
›How long does it take for losartan to lower blood pressure in a teenager?
›Can losartan be compounded into a liquid for a teenager who cannot swallow tablets?
›What blood potassium level should prompt a call to the prescriber?
›Should losartan be held during a stomach virus or vomiting illness?
›What are the signs of a serious allergic reaction to losartan?
›Does a teenager need to check blood pressure at home while on losartan?
›Can losartan be used for Marfan syndrome in teenagers?
References
- FDA. Cozaar (losartan potassium) Prescribing Information. Revised 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/020386s062lbl.pdf
- FDA. Pediatric Labeling Information, Losartan Potassium (Cozaar). Drug Approvals and Databases. https://www.fda.gov/drugs/development-resources/pediatric-labeling-information-database
- Wühl E, Trivelli A, Picca S, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639-1650. https://www.nejm.org/doi/full/10.1056/NEJMoa0902066
- Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med. 2009;361(1):40-51. https://www.nejm.org/doi/full/10.1056/NEJMoa0808400
- Lacro RV, Dietz HC, Sleeper LA, et al. Atenolol versus losartan in children and young adults with Marfan's syndrome. N Engl J Med. 2014;371(22):2061-2071. https://www.nejm.org/doi/full/10.1056/NEJMoa1404731
- Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904. https://pubmed.ncbi.nlm.nih.gov/28827377/
- Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury. BMJ. 2013;346:e8525. https://www.bmj.com/content/346/bmj.e8525
- Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med. 2004;351(6):585-592. https://www.nejm.org/doi/full/10.1056/NEJMra035279
- Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012;110(3):383-391. https://pubmed.ncbi.nlm.nih.gov/22521430/
- Cooper WO, Hernandez-Diaz S, Arbogast PG, et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354(23):2443-2451. https://www.nejm.org/doi/full/10.1056/NEJMoa055202
- National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl):555-576. https://pubmed.ncbi.nlm.nih.gov/15286277/
- ESCAPE Trial Group. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639-1650. https://pubmed.ncbi.nlm.nih.gov/19846849/